Riskpilot← Back to searchSign inGet full accessSTIFTELSEN TIL DIABETESFORSKNING
STIActiveOrg 938443653Activities of other membership organisations n.e.c. · NACE 9499Est. 19650 employeeswww.unifor.no
Revenue 2024
NOK 1,2M
+10% vs 2023
EBITDA margin
97.6%
+10% vs 2023
Equity ratio
99.3%
Financial strength
Net profit 2024
NOK 1,1M
+4% vs 2023
| Revenue | NOK 1,2M | +10% |
| EBITDA | NOK 1,2M | +10% |
| Net profit | NOK 1,1M | +4% |
| Total assets | NOK 7,9M | +16% |
| Equity | NOK 7,8M | +16% |
| Employees | 0 | — |
Legal name
STIFTELSEN TIL DIABETESFORSKNING
Org number
938443653
Legal form
Stiftelse
NACE code
9499 · Activities of other membership organisations n.e.c.
Founded
4. mai 1965
Share capital
—
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Address
Website
www.unifor.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 716 | 846 | 744 | 1 093 | 1 201 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 692 | 822 | −765 | 1 069 | 1 171 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 692 | 822 | −765 | 1 069 | 1 171 |
| Net financials | −82 | −90 | 4 | −60 | −119 |
| Profit before tax | 610 | 732 | −765 | 1 009 | 1 052 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | 610 | 732 | −765 | 1 009 | 1 052 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 5 788 | 6 579 | 5 784 | 6 763 | 7 874 |
| Equity | 5 788 | 6 519 | 5 754 | 6 763 | 7 815 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 60 | 30 | 0 | 59 |
| Total debt | 0 | 60 | 30 | 0 | 59 |
EBITDA margin
97.6%
This company
15.8%
Market median
+518% vs market
20202024
Equity ratio
99.3%
This company
38.2%
Market median
+160% vs market
20202024
Return on equity
13.5%
This company
18.4%
Market median
+27% vs market
20202024
Net profit margin
87.6%
This company
8.1%
Market median
+981% vs market
20202024
Asset turnover
0.15×
This company
1.12×
Market median
-87% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
HJ Contact Person | Contact Person | 2008 |
| Name | Role | Member since |
|---|---|---|
| Current (8) | ||
| Board of Directors | 2026 | |
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2021 | |
| Board of Directors | 2026 | |
| Board of Directors | 2021 | |
| Former (1) | ||
| Chairman | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of STIFTELSEN TIL DIABETESFORSKNING also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Jørgen Stang | Contact Person | 0 companies |
| Anders Malthe-Sørenssen | Board of Directors | 0 companies |
| Bjarne Borgersen | Chairman | 0 companies |
| Leif Sven Helmich Pedersen | Chairman | 0 companies |
| Stine Marie Ulven | Board of Directors | 0 companies |
| Christina Stray | Board of Directors | 0 companies |
| Øyvind Østerud | Board of Directors | 0 companies |
| Anders Elverhøi | Board of Directors | 0 companies |
| Einar Lie | Board of Directors | 0 companies |
| Benedicte Elisabeth Bakke Agerup | Board of Directors | 0 companies |